Pulse Biosciences (PLSE) Liabilities and Shareholders Equity (2015 - 2026)

Pulse Biosciences' Liabilities and Shareholders Equity history runs 11 years deep, the most recent figure standing at $94.5 million for Q4 2025.

• In Q4 2025, Liabilities and Shareholders Equity fell 28.63% year-over-year to $94.5 million; the TTM figure through Dec 2025 stood at $456.9 million (up 45.01% YoY), while the FY2025 annual figure was $94.5 million, down 28.63% from the prior year.
• Liabilities and Shareholders Equity for Q4 2025 stood at $94.5 million, down from $108.8 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $133.4 million in Q1 2025, with the low at $39.5 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $76.3 million (2022), against an average of $78.7 million.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity plunged 50.92% in 2022, then surged 197.44% in 2025.
• Pulse Biosciences' Liabilities and Shareholders Equity stood at $59.2 million in 2021, then jumped by 31.65% to $77.9 million in 2022, then slipped by 24.04% to $59.2 million in 2023, then surged by 123.92% to $132.5 million in 2024, then fell by 28.63% to $94.5 million in 2025.
• Business Quant data shows PLSE's Liabilities and Shareholders Equity at $94.5 million in Q4 2025, $108.8 million in Q3 2025, and $120.3 million in Q2 2025.